The United Kingdom and the United States have secured a key bilateral deal that will ensure zero import taxes on British drug exports going into the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to boost expenditure on medicines through the National Health Service (NHS). This move ensures that tariffs on these crucial exports will be held at nothing for a timeframe of the next three years.
This development follows previous statements to significantly raise import taxes on branded pharmaceutical products, with potential rates discussed up to double the cost.
"This arrangement with the United Kingdom reinforces the worldwide climate for new treatments and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release said.
Economic Significance
Medicines are one of the the United Kingdom's biggest goods shipped to the America, which is by far the primary destination for leading UK drugmakers.
Export figures reveal that in the 12 months leading up to September, the UK sold drugs worth over eleven billion pounds to the US. This amount made up nearly one-fifth of British export trade in that period.
"This guarantee protects work, boosts capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," a government official stated.
Key NHS Changes
The pact involves several notable commitments from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to raise total health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must refund to the NHS to control costs will be restricted at 15%. Previously, refunds topped 20%.
Recent Tensions
The deal comes amid a long-running tension between the drug companies and the ministers over drug pricing and approval rates.
These tensions were heightened by claims that US customers were charged significantly more for the equivalent treatments than people in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or scrapped, while substantial investments have been pledged toward US facilities.
One official stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the last ten years.
